Apigenin vs Luteolin
Two dietary flavonoids marketed on adjacent claims — sleep and NAD⁺ for one, mast-cell and neuroinflammation for the other — with the same underlying problem: almost no human trial data on the isolated compound itself.
Apigenin
Found in chamomile, parsley, celery
The CD38-inhibition/NAD⁺ story is mechanistic and mouse-derived; the only real human RCT evidence is for whole chamomile extract (which contains apigenin among many compounds) in generalized anxiety disorder, not for isolated apigenin or for sleep specifically.
Full Apigenin evidence reviewLuteolin
3',4',5,7-tetrahydroxyflavone, cynaroside
A genuinely strong mast-cell and microglial mechanism whose entire human record is combination products — and the one placebo-controlled test of luteolin alone was negative.
Full Luteolin evidence reviewSide by side
| Apigenin | Luteolin | |
|---|---|---|
| Marketed for | Sleep, relaxation, CD38/NAD⁺ support | Mast-cell stabilisation, brain fog / neuroinflammation, allergy, senolytic |
| Evidence grade | Preclinical / minimal | Preclinical / minimal |
| Family | NAD⁺ & mitochondrial | Immune & inflammation |
| Key human source | Chamomile extract RCT, J Clin Psychopharmacol 2009 | Placebo-controlled crossover screen, IJERPH 2021 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Apigenin's best human evidence is for whole chamomile extract in generalized anxiety disorder, not for isolated apigenin or for sleep specifically. Luteolin's human evidence is the same shape — real mast-cell biology in the lab, but almost every human trial tested it inside a combination formula, not alone. Both are cases where a real, specific lab mechanism gets marketed several steps beyond what any trial has shown for the pure compound.
Apigenin fits if
Sleep or a CD38/NAD⁺ angle is the specific interest, understanding the human case rests on chamomile extract, not apigenin alone.
Luteolin fits if
Mast-cell-related symptoms are the target, understanding almost no trial isolated luteolin's own contribution from the combination formulas it was tested in.